Stock A145020 HUGEL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hugel, Inc.

Equities

A145020

KR7145020004

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
191,000 KRW -0.68% Intraday chart for Hugel, Inc. -12.18% +27.84%
May. 16 Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on February 13, 2024. CI
May. 16 Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on November 13, 2023. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,342,298 2,352,299 1,864,449 1,597,992 1,675,393 1,983,084 - -
Enterprise Value (EV) 2 860 1,843 1,406 1,219 1,287 1,541 1,463 1,543
P/E ratio 37.5 x 56.2 x 33 x 29.7 x 18.8 x 22.4 x 16.7 x 13.9 x
Yield - - - - - - - -
Capitalization / Revenue 6.56 x 11.1 x 7.61 x 5.67 x 5.24 x 5.35 x 4.57 x 4.07 x
EV / Revenue 4.2 x 8.73 x 5.74 x 4.33 x 4.03 x 4.16 x 3.37 x 3.17 x
EV / EBITDA 11.1 x 20.8 x 12.6 x 10.6 x 9.78 x 9.69 x 7.48 x 6.52 x
EV / FCF 13.3 x 32.2 x 22.7 x 25.2 x 13.7 x 20.1 x 15.6 x 13.6 x
FCF Yield 7.52% 3.11% 4.41% 3.96% 7.3% 4.98% 6.4% 7.34%
Price to Book 2.37 x 3.15 x 2.41 x 2.03 x 2.4 x 2.65 x 2.28 x 1.92 x
Nbr of stocks (in thousands) 10,126 12,526 12,146 11,846 11,214 10,383 - -
Reference price 3 132,565 187,800 153,500 134,900 149,400 191,000 191,000 191,000
Announcement Date 3/12/20 2/9/21 2/10/22 2/9/23 2/14/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 204.6 211 245.2 281.7 319.7 370.4 433.8 486.9
EBITDA 1 77.57 88.76 111.5 115.4 131.6 159 195.5 236.7
EBIT 1 68.09 78.21 97.14 102.5 117.8 142.5 180.9 220.2
Operating Margin 33.28% 37.06% 39.62% 36.39% 36.86% 38.48% 41.69% 45.23%
Earnings before Tax (EBT) 1 69.73 81.7 89.01 66.51 132.8 145.1 183.3 212.1
Net income 1 44.61 51.87 57.52 57.66 92.3 101.7 133.5 157.6
Net margin 21.81% 24.58% 23.46% 20.47% 28.87% 27.44% 30.77% 32.37%
EPS 2 3,532 3,344 4,658 4,545 7,934 8,509 11,428 13,723
Free Cash Flow 3 64,701 57,325 62,061 48,272 93,988 76,667 93,650 113,333
FCF margin 31,627.96% 27,164.44% 25,315.05% 17,137.58% 29,399.09% 20,696.65% 21,589.18% 23,274.62%
FCF Conversion (EBITDA) 83,406.25% 64,581.67% 55,680.25% 41,840.33% 71,396.59% 48,214.85% 47,899.33% 47,883.47%
FCF Conversion (Net income) 145,029.21% 110,517.41% 107,903.34% 83,717.39% 101,828.84% 75,415.89% 70,157.34% 71,892.28%
Dividend per Share 2 - - - - - - - -
Announcement Date 3/12/20 2/9/21 2/10/22 2/9/23 2/14/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 61.01 64.9 67.4 70.68 85.49 64.38 81.56 84.82 88.94 74.31 93.8 101.4 104 107.6 113.2
EBITDA 1 - - - - 32.82 21.88 31.38 37.69 40.34 27.84 41 45.5 46.5 - -
EBIT 1 19.74 24.99 22.32 24.77 31.17 18.5 27.98 34.55 36.79 23.96 36.62 42.75 40.6 39.7 43.1
Operating Margin 32.35% 38.5% 33.12% 35.05% 36.46% 28.74% 34.31% 40.74% 41.36% 32.24% 39.05% 42.16% 39.05% 36.9% 38.07%
Earnings before Tax (EBT) 1 11.42 22.14 23.16 31.94 -12.58 24.28 30.87 53.65 24.01 29.4 35.5 38 41.2 40.8 44.2
Net income 1 3.717 14.98 14.78 25.76 2.143 16.38 21.11 39.39 15.42 20.8 24.65 27.05 29.45 29 31.4
Net margin 6.09% 23.08% 21.93% 36.45% 2.51% 25.43% 25.88% 46.44% 17.34% 28% 26.28% 26.68% 28.32% 26.95% 27.74%
EPS - - - - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 2/10/22 5/11/22 8/10/22 11/10/22 2/9/23 5/10/23 8/9/23 11/13/23 2/14/24 5/9/24 - - - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 482 509 458 379 388 442 520 440
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 2 64,701 57,325 62,061 48,272 93,988 76,667 93,650 113,333
ROE (net income / shareholders' equity) 6.25% 5.81% 7.58% 7% 12.1% 12.6% 14.8% 14.8%
ROA (Net income/ Total Assets) 4.92% 4.54% 5.87% 5.33% 9.41% 10.8% 11.4% 12.3%
Assets 1 906.5 1,143 979.4 1,082 981.3 941.3 1,168 1,287
Book Value Per Share 3 55,845 59,612 63,708 66,477 62,204 71,943 83,831 99,509
Cash Flow per Share 3 5,330 5,917 6,606 6,817 9,704 7,788 11,028 14,948
Capex 1 12.3 17 23.9 33 23.7 22 31.5 32
Capex / Sales 6.01% 8.04% 9.74% 11.7% 7.42% 5.94% 7.26% 6.57%
Announcement Date 3/12/20 2/9/21 2/10/22 2/9/23 2/14/24 - - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Hugel, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
191,000 KRW
Average target price
224,889 KRW
Spread / Average Target
+17.74%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
HUGEL, INC. Stock Hugel, Inc.
+27.84% 1.43B
CSL LIMITED Stock CSL Limited
-1.85% 89.87B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-3.95% 37.57B
UCB Stock UCB
+61.72% 26.47B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-22.14% 14.25B
INCYTE CORPORATION Stock Incyte Corporation
-7.96% 12.99B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.33% 11.93B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-46.33% 10.84B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.42% 9.11B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-19.53% 7.32B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A145020 Stock
  4. Financials Hugel, Inc.